Summary by Futu AI
On April 25, 2024, Apollomics Inc., a clinical-stage biopharmaceutical company, announced that its Chinese partner, Avistone Biotechnology Co. Ltd., received approval from the National Medical Products Administration (NMPA) of China for the drug vebreltinib as a treatment for gliomas with MET fusion gene. This approval, based on the results of a Phase 2/3 trial, marks vebreltinib as the first c-Met inhibitor approved for Central Nervous System (CNS) tumors with c-Met alteration. The drug is indicated for adult patients with specific types of astrocytoma or glioblastoma who have failed previous treatments. The approval follows a previous NMPA approval for vebreltinib in treating non-small cell lung cancer (NSCLC). Apollomics Inc. is also conducting a global Phase 2 study, SPARTA, to investigate the efficacy and safety of vebreltinib in various cancers, including NSCLC. The company has a pipeline of nine drug candidates, with six in clinical development. The press release also includes forward-looking statements regarding the company's clinical trials, business plans, and objectives.